deferoxamine has been researched along with Glial Cell Tumors in 13 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| " 5-aminolevulinic acid (ALA) is metabolized to fluorescent protoporphyrin IX (PpIX) specifically in tumor cells, and therefore clinically used as a reagent for photodynamic diagnosis (PDD) and therapy (PDT) of cancers including gliomas." | 7.85 | Enhancement of 5-aminolevulinic acid-based fluorescence detection of side population-defined glioma stem cells by iron chelation. ( Hagiya, Y; Kokubu, Y; Murota, Y; Ogura, SI; Sugiyama, Y; Tabu, K; Taga, T; Wang, W, 2017) |
| " 5-aminolevulinic acid (ALA) is metabolized to fluorescent protoporphyrin IX (PpIX) specifically in tumor cells, and therefore clinically used as a reagent for photodynamic diagnosis (PDD) and therapy (PDT) of cancers including gliomas." | 3.85 | Enhancement of 5-aminolevulinic acid-based fluorescence detection of side population-defined glioma stem cells by iron chelation. ( Hagiya, Y; Kokubu, Y; Murota, Y; Ogura, SI; Sugiyama, Y; Tabu, K; Taga, T; Wang, W, 2017) |
| " We found dihydroartemisinin (5-25 microM) inhibited the growth and induced apoptosis of C6 cells in a concentration- and time-dependent manner; however, it was much less toxic to rat primary astrocytes." | 1.34 | Dihydroartemisinin exerts cytotoxic effects and inhibits hypoxia inducible factor-1alpha activation in C6 glioma cells. ( Huang, XJ; Lu, YB; Ma, ZQ; Wei, EQ; Zhang, WP, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (38.46) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lo Dico, A | 1 |
| Valtorta, S | 1 |
| Martelli, C | 1 |
| Belloli, S | 1 |
| Gianelli, U | 1 |
| Tosi, D | 1 |
| Bosari, S | 1 |
| Degrassi, A | 1 |
| Russo, M | 1 |
| Raccagni, I | 1 |
| Lucignani, G | 1 |
| Moresco, RM | 1 |
| Ottobrini, L | 1 |
| Ivanov, SD | 1 |
| Semenov, AL | 1 |
| Kovan'ko, EG | 1 |
| Yamshanov, VA | 1 |
| Wang, W | 1 |
| Tabu, K | 1 |
| Hagiya, Y | 1 |
| Sugiyama, Y | 1 |
| Kokubu, Y | 1 |
| Murota, Y | 1 |
| Ogura, SI | 1 |
| Taga, T | 1 |
| Lu, H | 1 |
| Li, Y | 1 |
| Shu, M | 1 |
| Tang, J | 1 |
| Huang, Y | 1 |
| Zhou, Y | 1 |
| Liang, Y | 1 |
| Yan, G | 1 |
| Yang, DI | 1 |
| Chen, SD | 1 |
| Yang, YT | 1 |
| Ju, TC | 1 |
| Xu, JM | 1 |
| Hsu, CY | 1 |
| Huang, XJ | 1 |
| Ma, ZQ | 1 |
| Zhang, WP | 1 |
| Lu, YB | 1 |
| Wei, EQ | 1 |
| Brodie, C | 1 |
| Siriwardana, G | 1 |
| Lucas, J | 1 |
| Schleicher, R | 1 |
| Terada, N | 1 |
| Szepesi, A | 1 |
| Gelfand, E | 1 |
| Seligman, P | 1 |
| Renton, FJ | 1 |
| Jeitner, TM | 1 |
| Philipov, P | 1 |
| Tsai, KL | 1 |
| Wang, SM | 1 |
| Chen, CC | 1 |
| Fong, TH | 1 |
| Wu, ML | 1 |
| Higuchi, Y | 1 |
| Matsukawa, S | 1 |
| Amoroso, S | 1 |
| Tortiglione, A | 1 |
| Secondo, A | 1 |
| Catalano, A | 1 |
| Montagnani, S | 1 |
| Di Renzo, G | 1 |
| Annunziato, L | 1 |
| Tjalkens, RB | 1 |
| Ewing, MM | 1 |
| Philbert, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metformin and Neo-adjuvant Temozolomide and Hypofractionated Accelerated Limited-margin Radiotherapy Followed by Adjuvant Temozolomide in Patients With Glioblastoma Multiforme (M-HARTT STUDY)[NCT02780024] | Phase 2 | 50 participants (Anticipated) | Interventional | 2015-03-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 other studies available for deferoxamine and Glial Cell Tumors
| Article | Year |
|---|---|
Validation of an engineered cell model for in vitro and in vivo HIF-1α evaluation by different imaging modalities.
Topics: Animals; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Shape; Deferoxamine; Glioma; Humans; | 2014 |
Effects of iron ions and iron chelation on the efficiency of experimental radiotherapy of animals with gliomas.
Topics: Animals; Deferoxamine; Glioma; Iron; Male; Radiotherapy; Rats; Rats, Wistar | 2015 |
Enhancement of 5-aminolevulinic acid-based fluorescence detection of side population-defined glioma stem cells by iron chelation.
Topics: Aminolevulinic Acid; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biotransforma | 2017 |
Hypoxia-inducible factor-1alpha blocks differentiation of malignant gliomas.
Topics: Animals; Cell Differentiation; Cell Line, Tumor; Cell Transformation, Neoplastic; Cobalt; Colforsin; | 2009 |
Carbamoylating chemoresistance induced by cobalt pretreatment in C6 glioma cells: putative roles of hypoxia-inducible factor-1.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Cell Survival; Cobalt; Def | 2004 |
Dihydroartemisinin exerts cytotoxic effects and inhibits hypoxia inducible factor-1alpha activation in C6 glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Artemisinins; Cell Hypoxia; Cell Proliferation; Cell Surv | 2007 |
Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of the cell cycle.
Topics: Aphidicolin; Cell Count; Cell Division; Deferoxamine; Drug Screening Assays, Antitumor; Ferritins; G | 1993 |
Cell cycle-dependent inhibition of the proliferation of human neural tumor cell lines by iron chelators.
Topics: Antineoplastic Agents; Cell Cycle; Cell Division; Deferoxamine; Glioma; Humans; Iron Chelating Agent | 1996 |
Suppression of tumor growth in experimental 9L gliosarcoma model by copper depletion.
Topics: Brain Neoplasms; Chelating Agents; Deferoxamine; Glioma; Humans; Penicillamine; Trace Elements | 1996 |
Mechanism of oxidative stress-induced intracellular acidosis in rat cerebellar astrocytes and C6 glioma cells.
Topics: Acidosis; Adenosine Triphosphate; Animals; Astrocytes; Catalase; Cells, Cultured; Cerebellum; Citric | 1997 |
Active oxygen-mediated chromosomal 1-2 Mbp giant DNA fragmentation into internucleosomal DNA fragmentation in apoptosis of glioma cells induced by glutamate.
Topics: Acetylcysteine; Animals; Antioxidants; Apoptosis; Ascorbic Acid; Catalase; Chromosomes; Deferoxamine | 1998 |
Sodium nitroprusside prevents chemical hypoxia-induced cell death through iron ions stimulating the activity of the Na+-Ca2+ exchanger in C6 glioma cells.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Amiloride; Animals; Bepridil; Calcium; Calcium Channel Block | 2000 |
Differential cellular regulation of the mitochondrial permeability transition in an in vitro model of 1,3-dinitrobenzene-induced encephalopathy.
Topics: Adenosine Triphosphate; Antioxidants; bcl-2-Associated X Protein; bcl-X Protein; Brain Diseases; Cal | 2000 |